About Syndax Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://syndax.com/
Frequently Asked Questions
What is the 52-week range for SNDX?
The 52-week high is $25.59 and the 52-week low is $12.99.
What is the P/E ratio for SNDX?
The P/E ratio data is currently unavailable.
What is the dividend yield for SNDX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -372.94%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -87.52%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 28.25.
Analyst Recommendation Trends
Wall Street analyst consensus for SNDX over the last few months:
Latest SNDX News
Claude AI Just Bought These 2 Pharma Stocks
Note: The stock trades discussed in this article come from AI Finance Labs, an investment experiment that operates publicly viewable portfolios directed by models including Claude, ChatGPT, Grok and DeepSeek. Anthropic’s Claude AI recently sold its positions in Ardelyx Inc. (NASDAQ: ARDX) and Aris Mining Corp. (NYSE: ARIS) and replaced them with Syndax Pharmaceuticals Inc. […]
Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases
Syndax achieved FDA approval for Revuforj in r/r mNPM1 AML and is pursuing pivotal studies to expand into 1st-line AML populations. Read why SNDX is a Strong Buy.
Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts
Syndax Pharmaceuticals, Inc. growth outlook: Revuforj AML data boosts confidence, $2B+ peak sales target, pipeline catalysts ahead. Click for this SNDX update.
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Citigroup's Biopharma Back to School Summit 2026 September 10, 2026 8:40 AM EDTCompany ParticipantsMichael Metzger - CEO...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting comm
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-08 | Metzger Michael A | +32,375 | - | - |
| 2026-07-08 | Metzger Michael A | -32,375 | $24.2402 | $784,776 |
| 2026-07-08 | Metzger Michael A | +32,375 | $6.38 | $206,553 |
| 2026-06-12 | Botwood Nicholas A.J. | +31,235 | - | - |
| 2026-06-12 | Botwood Nicholas A.J. | -31,235 | $18.14 | $566,603 |
| 2026-06-12 | Botwood Nicholas A.J. | +31,235 | $13.82 | $431,668 |
| 2026-06-11 | Botwood Nicholas A.J. | +22,515 | - | - |
| 2026-06-11 | Botwood Nicholas A.J. | -34,280 | $18 | $617,040 |
| 2026-06-11 | Botwood Nicholas A.J. | +22,515 | $13.82 | $311,157 |
| 2026-06-01 | Goldan Keith A. | -1,177 | $18.99 | $22,351 |
| 2026-06-01 | Metzger Michael A | -6,847 | $18.99 | $130,025 |
| 2026-02-09 | Metzger Michael A | -17,159 | $21.028 | $360,819 |
| 2026-02-09 | Goldan Keith A. | -3,410 | $21.028 | $71,705 |
| 2026-02-06 | Metzger Michael A | -7,412 | $20.62 | $152,835 |
| 2026-02-06 | Goldan Keith A. | -2,082 | $20.62 | $42,931 |
| 2026-02-04 | Metzger Michael A | +440,000 | $20.43 | $8,989,200 |
| 2026-02-04 | Metzger Michael A | +144,600 | - | - |
| 2026-02-04 | Metzger Michael A | +73,000 | - | - |
| 2026-02-04 | Goldan Keith A. | +118,000 | $20.43 | $2,410,740 |
| 2026-02-04 | Goldan Keith A. | +30,750 | - | - |
| 2026-02-04 | Goldan Keith A. | +21,500 | - | - |
| 2026-02-04 | Jarrett Jennifer | +24,000 | - | - |
| 2026-02-04 | Huber Martin H. Jr. | +24,000 | - | - |
| 2026-02-04 | Botwood Nicholas A.J. | +144,700 | $20.43 | $2,956,221 |
| 2026-02-04 | Botwood Nicholas A.J. | +36,000 | - | - |
| 2026-02-04 | Botwood Nicholas A.J. | +24,000 | - | - |
| 2026-02-04 | Rizo Aleksandra | +24,000 | - | - |
| 2026-02-04 | Legault Pierre | +24,000 | - | - |
| 2026-02-04 | Katkin Keith | +24,000 | - | - |
| 2026-02-04 | Podlesak Dennis | +48,000 | - | - |
| 2026-01-30 | Goldan Keith A. | +1,219 | $8.48 | $10,337 |
| 2025-12-01 | Goldan Keith A. | -1,224 | - | - |